Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
CPT: Pharmacometrics & Systems Pharmacology|July 28, 2021
ModVizPop: A shiny interface for empowering teams to perform interactive pharmacokinetic/pharmacodynamic simulationsPavan Vaddady, Bhargava Kandala
Antimicrobial Agents and Chemotherapy|September 2, 2020
Population Pharmacokinetic and Pharmacodynamic Analysis To Evaluate a Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in People Living with HIV-1Pavan Vaddady, Bhargava Kandala, Ka Lai Yee
The Journal of Allergy and Clinical Immunology. in Practice|September 13, 2014
Nonprescription racemic epinephrine for asthmaPritish Mondal, Bhargava Kandala, Richard Ahrens, et al.
Clinical and Translational Science|July 3, 2026
Population Pharmacokinetic, Exposure-Response Efficacy and Safety Analyses of Favezelimab in Patients With Solid TumorsMitali Gaurav, Heather Barcomb, Kelly F Maxwell, et al.
Antimicrobial Agents and Chemotherapy|September 25, 2019
Doravirine exposure and HIV-1 suppression after switching from an efavirenz-based regimen to doravirine/lamivudine/tenofovir disoproxil fumarateWayne Greaves, Hong Wan, Ka Lai Yee, et al.
Clinical Pharmacology and Therapeutics|January 1, 2020
A Model-Informed Drug Discovery and Development Strategy for the Novel Glucose-Responsive Insulin MK-2640 Enabled Rapid Decision MakingSandra A G Visser, Bhargava Kandala, Craig Fancourt, et al.
Ebiomedicine|October 1, 2022
Accelerating model-informed decisions for COVID-19 vaccine candidates using a model-based meta-analysis approachBhargava Kandala, Nele Plock, Akshita Chawla, et al.
Clinical Pharmacology and Therapeutics|August 21, 2018
Clinical Evaluation of MK-2640: An Insulin Analog With Glucose-Responsive PropertiesAlexander W Krug, Sandra A G Visser, Kuenhi Tsai, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 15, 2021
Single Oral Doses of MK-8507, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor, Suppress HIV-1 RNA for a WeekDirk Schürmann, Deanne Jackson Rudd, Andrea Schaeffer, et al.
Investigational New Drugs|February 7, 2024
CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trialAndrew J Armstrong, Ravit Geva, Hyun Cheol Chung, et al.
Pageof 2